Before You Sign with a Canadian CMO: The Health Canada GMP Checklist Your Regulatory Team Needs

Most sponsor companies discover the gaps in their CMO vetting process during a Health Canada inspection — not before one. By then, the manufacturing agreement is signed, product is on the line, and the regulatory team is scrambling to produce documentation their contract manufacturer never actually had in place.

Canada GMP compliance under Division 2 of Part C of the Food and Drug Regulations is non-negotiable for any drug that gets manufactured, packaged, tested, or imported here. But the regulations don’t just bind the manufacturer — they bind the sponsor too. And that’s a distinction most CMO agreements still don’t address clearly enough.

What Health Canada Actually Requires Before Manufacturing Begins

Your contract manufacturer must hold a valid Drug Establishment Licence (DEL), issued under Section C.01A of the Food and Drug Regulations. The DEL isn’t just paperwork — it specifies exactly which activities a site is licensed to perform. A site licensed for manufacturing may not be licensed for sterile filling. A site licensed for solid oral dosage forms may not cover semi-solids. You’d be surprised how often sponsor teams assume a DEL covers more than it does.

Beyond the DEL, Health Canada’s primary GMP reference document is GUI-0001, Good Manufacturing Practices (GMP) Guidelines. This sets the baseline for everything from premises and equipment to production records and quality control. Health Canada inspectors treat deviations from it seriously — documentation deficiencies consistently rank as the most commonly cited category of observations across drug establishment types in Canada.

And then there’s the Quality Agreement. ICH Q10, which Health Canada formally endorses, requires a written agreement between sponsor and manufacturer defining who is responsible for each GMP activity. Inspectors increasingly ask to see the Quality Agreement on-site. If it doesn’t exist, or if it’s vague about batch release responsibilities, that’s an observation. If it contradicts what’s actually happening on the floor, that’s a major one.

The Canada GMP Checklist: Seven Documents to Request Before Signing

This is where most vetting processes fall short. Companies ask for the DEL number and a copy of the latest audit report. That’s a starting point, not a checklist.

Here’s what your regulatory team should be requesting and reviewing before any manufacturing agreement is executed:

1. Current Drug Establishment Licence — with activity scope confirmed in full

Ask for the actual licence document, not a summary. Compare the listed activities against everything you intend the CMO to do for you. If the scope doesn’t match, you’re looking at either a licensing amendment — which takes a realistic 3 to 6 months for a DEL amendment at Health Canada — or a fundamental mismatch between what you need and what this site can legally provide.

2. Most recent Health Canada GMP inspection report and CAPA response

Health Canada publishes inspection outcomes in a searchable database, so you can verify the record independently. A site with zero observations in its last inspection cycle isn’t necessarily stronger than one that had 10 minor observations and a thorough, completed CAPA. The latter often demonstrates a more mature quality system. What you’re looking for is evidence of how the site responds to findings, not just whether they get them.

3. SOPs for your specific product type — the actual documents, not a list

At minimum: batch record creation, change control, deviation handling, and environmental monitoring. A CMO that’s reluctant to share these before signing is already telling you something about how transparent the relationship will be once you’re committed.

4. Equipment qualification and calibration records

Under Health Canada GMP guidelines, all equipment used in manufacturing, testing, and packaging must be qualified and maintained under a documented program. Ask for the equipment list relevant to your product and evidence of current qualification status. Out-of-specification calibration records — or equipment used beyond its requalification date — are observations waiting to happen during your next Health Canada inspection.

5. Quality Agreement template or working draft

See their standard template before you negotiate your own. Some CMOs use agreements so heavily weighted toward their own protection that they effectively transfer all GMP responsibility to the sponsor. Others use outdated templates that predate ICH Q10 or current Health Canada expectations. Seeing the starting point is diagnostic.

6. A redacted Annual Product Review (APR) for a comparable product type

Under C.02.011 of the Food and Drug Regulations, manufacturers must conduct annual product reviews. A well-structured APR reveals whether the site is genuinely evaluating trends — rejection rates, process deviations, out-of-specification results — or simply satisfying an auditor. Ask for a redacted example. If they can’t or won’t provide one, that’s informative.

7. Validation Master Plan

For any new product or process, you need to understand the site’s approach to process validation. Health Canada aligns with ICH Q8 and Q9 principles for pharmaceutical development and quality risk management. A CMO without an active, current Validation Master Plan — or one where the plan describes future intent rather than current practice — is a measurable risk factor before manufacturing ever starts.

Red Flags That Don’t Show Up in a Facility Audit

Auditing a CMO facility is standard practice. But the audit itself can miss things the documentation review catches — and vice versa. Three patterns are worth flagging specifically.

Turnover in the Qualified Person or Head of Quality role. If a site has had 3 or more individuals in that role within the last 24 months, ask why directly. Regulatory continuity matters, and institutional knowledge in quality leadership doesn’t rebuild quickly. Health Canada inspectors who visit a site repeatedly notice when the QP keeps changing.

DEL scope creep in the sales pitch. Some CMOs will confidently tell you they can handle activities that aren’t on their current licence — “we can add that activity, it’s straightforward.” A DEL amendment is never straightforward. It requires a Health Canada review, potentially a site inspection, and a timeline that’s measured in months. If a potential CMO treats their DEL as a flexible document, they don’t fully understand what maintaining it involves.

Recurring observations across audit cycles. When reviewing audit history, look for findings that appear in 2 or more consecutive cycles. A deviation that shows up once can be an anomaly. One that appears in three consecutive audits is a systemic issue the site has not resolved. Health Canada inspectors track this pattern across inspection cycles and treat repeat findings with escalating seriousness.

Building a Manufacturing Agreement That Holds Up Under Scrutiny

A well-structured CMO agreement does two things generic templates often don’t: it maps directly to Canada GMP requirements by regulation number, and it assigns responsibility by function rather than by company. “Health Canada compliance” is not a responsibility that can be assigned wholesale to one party. Specific activities can — and must — be assigned with clarity.

Before your legal team finalizes the agreement, your regulatory team should walk through it section by section against the Quality Agreement. Every significant GMP activity should appear in exactly one document, assigned to exactly one party, with a defined escalation process when something goes wrong. If a manufacturing deviation occurs and the agreement doesn’t clearly define who classifies it, who investigates it, and who has final authority on disposition, you’ll discover that ambiguity at the worst possible moment.

Health Canada’s expectation — expressed consistently through inspection findings and guidance documents — is that both the CMO and the sponsor understand GMP obligations as shared and interlocking. The CMO runs the processes. The sponsor owns the product. That distinction carries real regulatory consequences, and a properly structured agreement reflects both sides of it.

Start the Quality Agreement negotiation before the commercial agreement is finalized. The time to discover your CMO’s DEL doesn’t cover the activity you need is not when your New Drug Submission is under review.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025 Accredited Analytical Testing for Canadian Drug Filings — Qalitex Laboratories provides accredited testing services that support Health Canada pharmaceutical submissions and CMO quality programs.
• EU GMP and European Market Entry for Canadian Manufacturers — Care Europe guides pharmaceutical companies through EU regulatory requirements for cross-border manufacturing and market access.